Sep. 24 at 12:05 PM
$PFE Key Pipeline Highlights⚖️ Berobenatide (PF-08653944): Ultra-long-acting injectable GLP-1 receptor agonist for chronic weight management in Phase 3.🧬 PF-08634404: Dual PD-1/VEGF inhibitor in-licensed from 3SBio, advancing in Phase 3 for colorectal and lung cancers.🫁 Sigvotatug Vedotin: Antibody-drug conjugate (ADC) evaluated for metastatic non-small cell lung cancer.🔬 Atirmociclib: Selective CDK4 inhibitor for HR+/HER2- metastatic breast cancer.🛡️ Vepdegestrant: ER+/HER2- metastatic breast cancer candidate in late-stage development.🦠 Vaccines: Late-stage candidates include a C. difficile vaccine and an mRNA-based flu/COVID combination vaccine.